Atorlip 20: Advanced Cholesterol Management with Atorvastatin
| Product dosage: 5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.48 | $74.33 (0%) | 🛒 Add to cart |
| 60 | $2.23 | $148.67 $133.60 (10%) | 🛒 Add to cart |
| 90 | $2.14 | $223.00 $192.86 (14%) | 🛒 Add to cart |
| 120 | $2.08 | $297.33 $250.12 (16%) | 🛒 Add to cart |
| 180 | $2.05 | $446.00 $368.65 (17%) | 🛒 Add to cart |
| 270 | $2.02
Best per pill | $669.00 $544.44 (19%) | 🛒 Add to cart |
Atorlip 20 is a prescription medication containing atorvastatin calcium, a potent lipid-lowering agent designed to manage elevated cholesterol levels and reduce cardiovascular risk. It belongs to the class of HMG-CoA reductase inhibitors (statins) and is indicated for patients requiring moderate to intensive lipid-lowering therapy. By effectively lowering LDL cholesterol and triglycerides while raising HDL cholesterol, Atorlip 20 supports long-term cardiovascular health and helps prevent atherosclerosis-related complications. This medication is typically prescribed as part of a comprehensive treatment plan that includes dietary modifications and lifestyle changes.
Features
- Contains 20 mg of atorvastatin calcium per tablet
- Film-coated, oval-shaped tablets for easy swallowing
- Available in blister packs of 10, 30, or 90 tablets
- Manufactured under strict pharmaceutical quality standards
- Requires prescription and regular lipid profile monitoring
- Suitable for long-term maintenance therapy
Benefits
- Significantly reduces LDL (“bad”) cholesterol levels by up to 50%
- Lowers triglyceride levels and modestly increases HDL (“good”) cholesterol
- Reduces risk of heart attack, stroke, and cardiovascular mortality
- Helps stabilize existing atherosclerotic plaques
- May improve endothelial function and reduce vascular inflammation
- Provides 24-hour lipid-lowering effect with once-daily dosing
Common use
Atorlip 20 is primarily prescribed for the treatment of hypercholesterolemia, including heterozygous and homozygous familial hypercholesterolemia. It is indicated for patients who have not achieved target lipid levels through diet and exercise alone. The medication is also used for primary prevention of cardiovascular disease in patients with multiple risk factors and for secondary prevention in those with established coronary artery disease. Clinical evidence supports its use in reducing the risk of myocardial infarction, stroke, and revascularization procedures in appropriate patient populations.
Dosage and direction
The recommended starting dose is one 20 mg tablet daily, which may be adjusted based on lipid response and tolerability. Administration can occur at any time of day, with or without food, though consistency in timing is recommended. Tablets should be swallowed whole with a glass of water and not crushed or chewed. Dosage adjustments should be made at intervals of 2-4 weeks, with maximum recommended dose of 80 mg daily for appropriate patients. Regular monitoring of liver enzymes and lipid profiles is essential before initiation and during therapy.
Precautions
Patients should undergo baseline liver function tests before starting therapy and periodically thereafter. Those with predisposing factors for myopathy should be carefully monitored. Atorlip 20 should be used cautiously in patients consuming substantial quantities of alcohol or with history of liver disease. Grapefruit juice should be avoided as it may increase drug concentrations. Patients should report unexplained muscle pain, tenderness, weakness, or brownish urine immediately. The medication may cause increased HbA1c and fasting serum glucose levels, requiring monitoring in diabetic patients.
Contraindications
Atorlip 20 is contraindicated in patients with active liver disease or unexplained persistent elevations of serum transaminases. It should not be used during pregnancy, breastfeeding, or in women of childbearing potential not using adequate contraception. Contraindications include hypersensitivity to atorvastatin or any component of the formulation. The medication is not recommended for patients with severe renal impairment unless closely monitored. Concomitant use with strong CYP3A4 inhibitors such as certain antifungals, macrolide antibiotics, or HIV protease inhibitors is contraindicated.
Possible side effects
Common side effects include headache, musculoskeletal pain, diarrhea, nausea, and joint pain. Less frequently reported effects include constipation, flatulence, indigestion, and insomnia. Serious but rare adverse reactions include myopathy, rhabdomyolysis with renal dysfunction, hepatotoxicity, and increased HbA1c levels. Some patients may experience memory loss, confusion, or elevated creatine kinase. Allergic reactions including rash, pruritus, and urticaria have been reported. Periodic monitoring can help detect and manage these potential effects early.
Drug interaction
Atorlip 20 interacts significantly with CYP3A4 inhibitors including itraconazole, ketoconazole, clarithromycin, and HIV protease inhibitors, increasing risk of myopathy. Concurrent use with gemfibrozil, other fibrates, or niacin may increase myopathy risk. Cyclosporine, danazol, and colchicine may potentiate adverse effects. Antacids containing magnesium and aluminum hydroxide may decrease atorvastatin absorption. Warfarin monitoring is recommended as atorvastatin may enhance anticoagulant effect. Careful consideration is needed when co-administering with digoxin, oral contraceptives, or certain antiretroviral regimens.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is almost time for the next scheduled dose. In that case, the missed dose should be skipped and the regular dosing schedule resumed. Patients should not take double or extra doses to make up for a missed dose. Consistency in daily administration is important for maintaining stable lipid-lowering effects. If multiple doses are missed, patients should consult their healthcare provider before resuming therapy.
Overdose
There is no specific antidote for atorvastatin overdose. Treatment should be supportive and symptomatic. Gastric lavage may be considered if performed soon after ingestion. Liver function tests and creatine kinase levels should be monitored. Supportive measures should include maintenance of hydration and electrolyte balance. Hemodialysis is not expected to significantly enhance elimination since atorvastatin is extensively protein bound. Medical attention should be sought immediately if overdose is suspected.
Storage
Store at room temperature between 15-30°C (59-86°F) in the original container. Protect from light, moisture, and excessive heat. Keep the medication in a secure location out of reach of children and pets. Do not use tablets that appear discolored, damaged, or beyond the expiration date printed on the packaging. Proper disposal of unused medication should follow local regulations or pharmacy guidance.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Atorlip 20 is a prescription medication that should be used only under the supervision of a qualified healthcare professional. Individual response to therapy may vary, and appropriate monitoring is essential. Patients should not initiate, discontinue, or modify dosage without consulting their physician. The prescribing information provided here may not include all possible uses, directions, precautions, or interactions.
Reviews
Clinical studies demonstrate that Atorlip 20 effectively reduces LDL cholesterol by approximately 43-50% at the 20 mg dose. In the ASCOT-LLA trial, atorvastatin 10 mg reduced coronary events by 36% in hypertensive patients with additional risk factors. The TNT trial showed that intensive lipid-lowering with atorvastatin 80 mg provided significant cardiovascular benefits compared to lower doses. Patient reviews typically report satisfactory lipid control with good tolerability at the 20 mg dose, though individual experiences vary. Healthcare professionals consider it a well-established option for moderate-intensity statin therapy with a favorable benefit-risk profile.